

Claims

1. A pharmaceutical composition comprising (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio] butanoic acid, a pharmaceutically acceptable bulking agent
5 and one or more antioxidants or chelating agents.
2. A pharmaceutical composition as claimed in claim 1 wherein the (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio]butanoic acid is in the form of its (1:1) compound with phosphoric acid, or a solvate thereof.
10
3. A pharmaceutical composition as claimed in claim 1 or claim 2 wherein the solvate is a hydrate.
4. A pharmaceutical composition as claimed in claim 3 wherein the hydrate is the
15 monohydrate.
5. A pharmaceutical composition as claimed in claim 3 wherein the hydrate is the trihydrate.
- 20 6. A pharmaceutical composition as claimed in any of claims 1 to 5 wherein the (2S)-2-amino-4-[[2-(ethanimidoethylamino)ethyl]thio]butanoic acid comprises from about 0.1 to about 5% by weight, the pharmaceutically acceptable bulking agent comprises from about 80 to about 99.5% by weight, and the antioxidant, chelating agent, or mixture thereof comprises from about 0.005 to about 5% by weight, based on the dry weight.
25
7. A pharmaceutical composition as claimed in any of claims 1 to 6 wherein the antioxidants or chelating agents are selected from the group comprising EDTA, malic acid, ascorbic acid and mixtures thereof.
- 30 8. A pharmaceutical composition as claimed in any of claims 1 to 7 wherein the pharmaceutically acceptable bulking agent comprises microcrystalline cellulose, starch or a mixture thereof.
9. A method for the treatment or prophylaxis of a clinical condition in a mammal, such
35 as a human, for which an inhibitor of nitric oxide synthase is indicated, which comprises administration of a pharmaceutical composition as claimed in any of claims 1 to 8.
10. A method as claimed in claim 9 wherein the clinical condition is selected from arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and
40 irritable bowel syndrome.
11. A pharmaceutical composition as claimed in any of claims 1 to 8 for use in medical therapy.

12. A pharmaceutical composition as claimed in claim 11 for use in the treatment or prophylaxis of a clinical condition in a mammal, such as a human, for which an inhibitor of nitric oxide synthase is indicated.
- 5 13. A pharmaceutical composition as claimed in claim 12 wherein the clinical condition is selected from arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and irritable bowel syndrome.
14. Use of a pharmaceutical composition as claimed in any of claims 1 to 8 in the
10 manufacture of a medicament for the prophylaxis or treatment of a clinical condition for which an inhibitor of nitric oxide synthase is indicated.
15. Use according to claim 14 wherein the clinical condition is selected from arthritis, asthma, rhinitis, chronic obstructive pulmonary disease, ileus, migraine, pain and irritable
15 bowel syndrome.